Change in the expression of gene transcription negative regulator SOCS1 in the patients with bronchial asthma and metabolic disorders

Cover Page

Cite item

Full Text

Abstract

Aim. Comprehensive study of the negative regulation components of cell signaling in the bronchial asthma (BA) patients with metabolic disorders.

Materials and methods. 113 people were examined: 63 patients with allergic BA (ABA), 50 patients with a non-allergic variant of the disease (NABA). SOCS1 mRNA expression was evaluated by reverse transcription PCR (RT-PCR). SOCS1 protein expression was investigated by immunoblotting. The determination of cytokine levels was carried out according to the standard protocol on a Bio-Plex flow fluorimeter.

Results. A significant and multidirectional change in the expression of SOCS1 mRNA was found at a body mass index >25 (greater than normal) in ABA and NABA. The positive correlations between SOCS1 mRNA expression and body mass index indicate the regulatory role of SOCS1 in leptin signaling. The spectra of correlations in ABA and NABA are different, it indicates the probable existence of specificity in the pathogenesis of these variants of the diseases.

Conclusion. The obtained data allow us to consider the complexity of regulation disorders occurring at different levels of cell signaling. The multifunctionality of the SOCS1 regulator provides complex control of cytokine signaling simultaneously in different signaling pathways in the BA with metabolic disorders.

About the authors

Lada N. Sorokina

Pavlov First Saint Petersburg State Medical University

Email: limvaleria@mail.ru
ORCID iD: 0000-0001-6193-2774

д.м.н., проф., каф. госпитальной терапии с курсом аллергологии и иммунологии им. акад. М.В. Черноруцкого

Russian Federation, St. Petersburg

Valeria V. Lim

Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: limvaleria@mail.ru
ORCID iD: 0000-0001-5799-3849

к.м.н., ст. лаборант каф. госпитальной терапии с курсом аллергологии и иммунологии им. акад. М.В. Черноруцкого.

Russian Federation, St. Petersburg

Valery N. Mineev

Pavlov First Saint Petersburg State Medical University

Email: limvaleria@mail.ru
ORCID iD: 0000-0003-0352-8137

д.м.н., проф., каф. госпитальной терапии с курсом аллергологии и иммунологии им. акад. М.В. Черноруцкого

Russian Federation, St. Petersburg

Mikhail A. Nyoma

Pavlov First Saint Petersburg State Medical University

Email: limvaleria@mail.ru
ORCID iD: 0000-0002-1268-9795

к.м.н., доц. каф. госпитальной терапии с курсом аллергологии и иммунологии им. акад. М.В. Черноруцкого

Russian Federation, St. Petersburg

Tatiana M. Lalayeva

Pavlov First Saint Petersburg State Medical University

Email: limvaleria@mail.ru
ORCID iD: 0000-0002-8990-3470

д.м.н., доц. каф. госпитальной терапии с курсом аллергологии и иммунологии им. акад. М.В. Черноруцкого

Russian Federation, St. Petersburg

References

  1. Минеев В.Н., Сорокина Л.Н. Экспрессия STAT6 в лимфоцитах периферической крови больных аллергической бронхиальной астмой. Мед. иммунология. 2007;9(4-5):405-11 [Mineev VN, Sorokina LN. The expression STAT6 in peripheral blood lymphocytes in patients with allergic bronchial asthma. Medical Immunology. 2007;9(4-5):405-11 (In Russ.)]. doi: 10.15789/1563-0625-2007-4-5-405-410
  2. Минеев В.Н., Сорокина Л.Н., Трофимов В.И. Фундаментальные и клинические аспекты JAK-STAT-сигнализации. СПб.: ВВМ, 2010 [Mineev VN, Sorokina LN, Trofimov VI. The fundamental and clinical aspects of the JAK-STAT signaling. Saint Petersburg: BBM, 2010 (In Russ.)].
  3. Yoshimura А, Suzuki M, Sakaguchi R, et al. SOCS, inflammation, and autoimmunity. Front Immunol. 2012;3:20. eCollection 2012. doi: 10.3389/fimmu.2012.00020
  4. Nicholson SE, Metcalf D, Sprigg NS, et al. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci U S A. 2005;102(7):2328-33. doi: 10.1073/pnas.0409675102
  5. Kasayama S, Tanemura M, Koga M, et al. Asthma is an independent risk for elevation of plasma C-reactive protein levels. Clin Chim Acta. 2009;399(1-2):79-82. doi: 10.1016/j.cca.2008.09.013
  6. Singh S, Bodas M, Bhatraju NK, et al. Hyperinsulinemia adversely affects lung structure and function. Am J Physiol Lung Cell Mol Physiol. 2016;310(9):837-45. doi: 10.1152/ajplung.00091.2015
  7. Brownlee М. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-34. doi: 10.1146/annurev.med.46.1.223
  8. Сорокина Л.Н., Иванов В.А., Лим В.В., и др. Особенности цитокинового спектра у больных неаллергической бронхиальной астмой в сочетании с сопутствующим сахарным диабетом 2 типа. Мед. иммунология. 2017;19(3):313-8 [Sorokina LN, Ivanov VA, Lim VV, et al. Cytokine profile features in the patient with nonallergic bronchial asthma with co-existing type 2 diabetes mellitus. Medical Immunology. 2017;19(3):313-8 (In Russ.)]. doi: 10.15789/1563-0625-2017-3-313-318
  9. Сорокина Л.Н., Минеев В.Н., Лим В.В. Роль негативных регуляторов транскрипции генов SOCS1, SOCS3 и SOCS5 в системе негативной регуляции клеточной сигнализации при бронхиальной астме. Терапевтически архив. 2017;89(3):43-7 [Sorokina LN, Mineev VN, Lim VV. Role of negative regulators of SOCS1, SOCS3, and SOCS5 gene transcription in the negative cell signaling regulation system in asthma. Terapevticheskii Arkhiv (Ter. Arkh). 2017;89(3):43-7 (In Russ.)]. doi: 10.17116/terarkh201789343-47
  10. Минеев В.Н., Лим В.В., Нема М.А., Трофимов В.И. Экспрессия негативного регулятора транскрипции генов белка SOCS1 в мононуклеарах периферической крови больных бронхиальной астмой. Цитокины и воспаление. 2012;11(2):23-7 [Mineev VN, Lim VV, Nyoma MA, Trofimov VI. The expression of SOCS proteins in negative regulation of JAK-STAT signaling. Cytokiny i vospalenie. 2012;11(2):23-7 (In Russ.)]
  11. Минеев В.Н., Сорокина Л.Н., Берестовская В.С., и др. Уровень лептина в плазме крови у пациентов с бронхиальной астмой. Клин. медицина. 2009;87(7):33-7 [Mineev VN, Sorokina LN, Berestovskaia VS, et al. Plasma leptin level in patients with bronchial asthma. Klinicheskaia meditsina. 2009;87(7):33-7 (In Russ.)]
  12. Fujimoto M, Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunology. 2003:24(12):659-66. PMID: 14644140
  13. Naka T, Tsutsui H, Fujimoto M, et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN- γ and IL-4 signaling in vivo. Immunity. 2001;14:535-45. PMID: 11371356
  14. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. J Tissue Antigens. 2006;67(1):1-9. doi: 10.1111/j.1399-0039.2005.00532.x
  15. Motta M, Accornero P, Baratta M. Leptin and prolactin modulate the expression of SOCS-1 in association with interleukin-6 and tumor necrosis factor-alpha in mammary cells: a role in differentiated secretory epithelium. Regul Pept. 2004;121(1-3):163-70. doi: 10.1016/j.regpep.2004.05.002
  16. Fazeli M, Zarkesh-Esfahani H, Wu Z, et al. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J Immunol Methods. 2006; 312(1-2):190-200. doi: 10.1016/j.jim.2006.03.011
  17. Ogbera A, Azenabor A, Ogundahunsi OA, et al. Cytokines, Type 2 DM and the Metabolic Syndrome. Nig Q J Hosp Med. 2013;23(4):318-22. PMID: 27276762
  18. Mori H, Okubo M, Okamura M, et al. Abnormalities of pulmonary function in patients with noninsulin-dependent diabetes mellitus. Intern Med. 1992;31(2):189-93. PMID: 1600265
  19. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase-1B. Dev Cell. 2002;2:497-503. PMID: 11970899
  20. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24(12):5434-46. doi: 10.1128/MCB.24.12.5434-5446.2004

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies